Dr Francesca Gay speaks to ecancer about the survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial. This study was presented at ASH 2020.
Dr Gay initially talks about what the Forte trial was about and then moves on tho explain what this study analysed. She says the aims of this analysis were to evaluate the progression-free survival of KRd induction-ASCT-KRd consolidation vs 12 cycles of KRd vs KCd induction-ASCT-KCd consolidation and the PFS of KR vs R maintenance. Secondary aims of this study were efficacy in different subgroups of patients and the safety of the maintenance phase. She then briefly mentions the methodology used in this analysis before moving on to explain the key results. She winds the interview up by talking about the future of this analysis.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.